Cartesian Therapeutics Inc banner

Cartesian Therapeutics Inc
NASDAQ:RNAC

Watchlist Manager
Cartesian Therapeutics Inc Logo
Cartesian Therapeutics Inc
NASDAQ:RNAC
Watchlist
Price: 6.39 USD 3.9% Market Closed
Market Cap: $169.4m

Wall Street
Price Targets

RNAC Price Targets Summary
Cartesian Therapeutics Inc

Wall Street analysts forecast RNAC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RNAC is 36.28 USD with a low forecast of 16.16 USD and a high forecast of 46.2 USD.

Lowest
Price Target
16.16 USD
153% Upside
Average
Price Target
36.28 USD
468% Upside
Highest
Price Target
46.2 USD
623% Upside
Cartesian Therapeutics Inc Competitors:
Price Targets
AMAL
Amalgamated Bank
10% Upside
MEDP
Medpace Holdings Inc
2% Upside
STG
Strip Tinning Holdings PLC
137% Upside
SSRM
SSR Mining Inc
27% Upside
VERK
Verkkokauppa.com Oyj
35% Upside

Revenue
Forecast

-7% / Year
Past Growth
112% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat
-7% / Year
Past Growth
112% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat

For the last 10 years the compound annual growth rate for Cartesian Therapeutics Inc's revenue is -7%. The projected CAGR for the next 3 years is 112%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-88%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-88%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RNAC's stock price target?
Price Target
36.28 USD

According to Wall Street analysts, the average 1-year price target for RNAC is 36.28 USD with a low forecast of 16.16 USD and a high forecast of 46.2 USD.

What is Cartesian Therapeutics Inc's Revenue forecast?
Projected CAGR
112%

For the last 10 years the compound annual growth rate for Cartesian Therapeutics Inc's revenue is -7%. The projected CAGR for the next 3 years is 112%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett